Research trends and hotspots in the immune microenvironment related to hepatocellular carcinoma: A bibliometric and visualization study

Table 1 The top 20 most productive institutions in the field

Rank	Institution	Country	Number of studies	Total citations	Average citation
1	Fudan University	China	165	4665	28.27
2	Sun Yat Sen University	China	149	4909	32.95
3	Zhejiang University	China	138	2552	18.49
4	Chinese Academy of Sciences	China	95	2124	22.36
5	Huazhong University of Science and Technology	China	95	1802	18.97
6	Chinese Academy of Medical Sciences-Peking Union Medical College	China	94	1116	11.87
7	Shanghai Jiao Tong University	China	88	1692	19.23
8	Southern Medical University-China	China	84	993	11.82
9	Zhengzhou University	China	81	1422	17.56
10	Nanjing Medical University	China	76	1577	20.75

Table 2 The top 10 most productive Journal in the field

Rank	Journal	Article counts	Percentage (3125)	Impact factor	Quartile in category
1	Frontiers in Immunology	220	7.04	7.3	Q1
2	Frontiers in Oncology	150	4.80	4.7	Q2
3	Cancers	131	4.19	5.2	Q2
4	International Journal of Molecular Sciences	74	2.37	5.6	Q1
5	Frontiers in Genetics	72	2.30	3.7	Q2
6	Frontiers in Cell and Developmental biology	49	1.57	5.5	Q2
7	Aging-us	43	1.38	5.2	Q2
8	Hepatology	41	1.31	14.0	Q1
9	Journal of Hepatocellular Carcinoma	41	1.31	4.1	Q2
10	Journal for Immunotherapy of Cancer	40	1.28	10.9	Q1

Table 3 Author's publications and co-citation

Rank	Author	Count	Location	Rank	Co-cited author	Citation
1	Fan J	31	China	1	Llovet JM	880
2	Zhou J	30	China	2	Jemal A	491
3	Zhang J	23	China	3	Finn RS	443
4	Li J	18	China	4	EL-Khoueiry AB	432
5	Zheng LM	17	China	5	Sung H	407
6	Kudo M	16	Japan	6	Kudo M	366
7	Wang W	16	China	7	Zhu AX	361
8	Wang Y	16	China	8	Sangro B	337
9	Greten TF	15	United States	9	Hanahan D	331
10	Gao Q	14	China	10	Bruix J	313

Table 4 List of co cited literature

Rank	Title	Journal IF (2021)	Author(s)	Total citations
1	Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries	CA-A Cancer Journal for Clinicians (IF = 354.7)	Sung H	393
2	Nivolumab in patients with advanced HCC (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial	Lancet (IF = 168.9)	El-Khoueiry AB	348
3	Atezolizumab plus Bevacizumab in Unresectable HCC	New England Journal of Medicine (IF = 158.5)	Finn RS	333
4	Pembrolizumab in patients with advanced HCC previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial	Lancet Oncology (IF = 51.1)	Zhu AX	259
5	HCC	Nature Reviews Disease Primers (IF = 81.5)	Llovet JM	246
6	HCC	New England Journal of Medicine (IF = 158.5)	Villanueva A	228
7	Lenvatinib versus sorafenib in first-line treatment of patients with unresectable HCC: A randomised phase 3 non-inferiority trial	Lancet (IF = 168.9)	Kudo M	196
8	A global view of HCC: trends, risk, prevention and management	Nature Reviews Gastroenterology and Hepatology (IF = 65.1)	Yang JD	194
9	Pembrolizumab As Second-Line Therapy in Patients With Advanced HCC in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial	Journal of Clinical Oncology (IF = 45.4)	Finn RS	186
10	Molecular therapies and precision medicine for HCC	Nature Reviews Clinical Oncology (IF = 78.8)	Llovet JM	162

HCC: Hepatocellular carcinoma; IF: Impact factor.